Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application

George Hajishengallis, Evlambia Hajishengallis, Tetsuhiro Kajikawa, Baomei Wang, Despina Yancopoulou, Daniel Ricklin, John D. Lambris

Research output: Contribution to journalReview articlepeer-review

39 Citations (Scopus)


Periodontitis is a dysbiotic inflammatory disease leading to the destruction of the tooth-supporting tissues. Current therapies are not always effective and this prevalent oral disease continues to be a significant health and economic burden. Early clinical studies have associated periodontitis with elevated complement activity. Consistently, subsequent genetic and pharmacological studies in rodents have implicated the central complement component C3 and downstream signaling pathways in periodontal host-microbe interactions that promote dysbiosis and inflammatory bone loss. This review discusses these mechanistic advances and moreover focuses on the compstatin family of C3 inhibitors as a novel approach to treat periodontitis. In this regard, local application of the current lead analog Cp40 was recently shown to block both inducible and naturally occurring periodontitis in non-human primates. These promising results from non-human primate studies and the parallel development of Cp40 for clinical use highlight the feasibility for developing an adjunctive, C3-targeted therapy for human periodontitis.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalSeminars in Immunology
Issue number3
Publication statusPublished - 2016 Jun 1
Externally publishedYes


  • C3
  • Complement
  • Compstatin cp40
  • Inflammation
  • Periodontitis
  • Primate models
  • Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application'. Together they form a unique fingerprint.

Cite this